Cargando…
A phase II JN-I-10 efficacy study of IDRF-based surgical decisions and stepwise treatment intensification for patients with intermediate-risk neuroblastoma: a study protocol
BACKGROUND: Few clinical trials have been reported for patients with intermediate-risk neuroblastoma because of the scarcity of the disease and the variety of clinical and biological characteristics. A multidisciplinary treatment that consists of multidrug chemotherapy and surgery is expected to lea...
Autores principales: | Iehara, Tomoko, Yoneda, Akihiro, Kikuta, Atsushi, Muraji, Toshihiro, Tokiwa, Kazuaki, Takahashi, Hideto, Teramukai, Satoshi, Takimoto, Tetsuya, Yagyu, Shigeki, Hosoi, Hajime, Tajiri, Tatsuro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218561/ https://www.ncbi.nlm.nih.gov/pubmed/32398048 http://dx.doi.org/10.1186/s12887-020-02061-5 |
Ejemplares similares
-
Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma
por: Yagyu, Shigeki, et al.
Publicado: (2016) -
Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma
por: Tomida, Akimasa, et al.
Publicado: (2021) -
RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker
por: Misawa, A, et al.
Publicado: (2009) -
Retrospective Analysis of INRG Clinical and Genomic Factors for 605 Neuroblastomas in Japan: A Report from the Japan Children’s Cancer Group Neuroblastoma Committee (JCCG-JNBSG) †
por: Ohira, Miki, et al.
Publicado: (2021) -
Shieldings: JN
Publicado: (2003)